Systemic Lupus Erythematosus

MPR Weekly Dose Podcast Episode 88

The FDA authorizes a postexposure prophylaxis for COVID-19; A new treatment is okay’d for lupus; A higher dose naloxone nasal spray became available; The risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.

Saphnelo Approved for Systemic Lupus Erythematosus

The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…

Clinical Challenge: Diffuse Rash Affecting Fingertips

A 28-year-old woman presents with fever and a diffuse rash. One year ago, the woman was  at the hospital dermatology department with fever, malar rash, arthralgia, and hematuria. Her medical history documented recurrent painful oral ulcers and photosensitivity. The diagnostic workup at that time revealed systemic lupus erythematosus (SLE) with cutaneous and renal involvement. The…